Every claim on this site has a citation.

Investigational. Phase 3 trials (TRIUMPH programme, Eli Lilly). Not approved by any regulatory authority for any indication.

1. [01]
   Jastreboff AM, Kaplan LM, Frías JP, et al.

   Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

   New England Journal of Medicine · 2023

   PubMed 37356066 ↗DOI ↗
2. [02]
   Rosenstock J, Frias J, Jastreboff AM, et al.

   Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

   The Lancet · 2023

   PubMed 37385275 ↗DOI ↗
3. [03]
   Coskun T, Urva S, Roell WC, et al.

   LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist

   Cell Metabolism · 2022

   PubMed 36198295 ↗DOI ↗

• NCT05929066

  TRIUMPH-1: Retatrutide in obesity
  Phase 3Registry ↗
• NCT05936151

  TRIUMPH-OUTCOMES: cardiovascular outcomes
  Phase 3Registry ↗

Investigational. Phase 3 trials under the TRIUMPH programme. Not approved anywhere.

1. [01]
   Jastreboff AM, et al.

   Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial

   NEJM · 2023

   PubMed 37356066 ↗DOI ↗
2. [02]
   Rosenstock J, et al.

   Retatrutide in people with type 2 diabetes — Phase 2

   The Lancet · 2023

   PubMed 37385275 ↗DOI ↗

• NCT05929066

  TRIUMPH-1: Retatrutide in obesity
  Phase 3Registry ↗

Investigational (Phase 3, TRIUMPH). Not approved anywhere.

1. [01]
   Jastreboff AM, et al.

   Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2

   NEJM · 2023

   PubMed 37356066 ↗DOI ↗

• NCT05929066

  TRIUMPH-1
  Phase 3Registry ↗

Investigational. In Phase 3 development by Novo Nordisk (CagriSema — combined with semaglutide). Not approved standalone.

1. [01]
   Enebo LB, et al.

   Cagrilintide with semaglutide for weight management — Phase 1b

   The Lancet · 2021

   PubMed 33894829 ↗DOI ↗
2. [02]
   Lau DCW, et al.

   Once-weekly cagrilintide for weight management — Phase 2

   The Lancet · 2021

   PubMed 34672970 ↗DOI ↗

• NCT05567796

  REDEFINE-1: CagriSema in obesity
  Phase 3Registry ↗
• NCT05813925

  REDEFINE-2: CagriSema in obesity with T2D
  Phase 3Registry ↗

Both peptides are preclinical-only; no completed Phase 3 human clinical trials. Published literature is extensive in rodent models (BPC-157) and mixed preclinical / limited clinical for Tβ4.

1. [01]
   Sikirić P, et al.

   BPC 157 and NSAIDs — review

   Current Pharmaceutical Design · 2013

   PubMed 22950504 ↗
2. [02]
   Goldstein AL, et al.

   Thymosin β4 — basic properties and clinical applications

   Expert Opinion on Biological Therapy · 2012

   PubMed 22506816 ↗DOI ↗
3. [03]
   Seiwerth S, et al.

   Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

   Frontiers in Pharmacology · 2021

   PubMed 34220518 ↗DOI ↗

Limited clinical evidence. Thymosin β-4 has been investigated in Phase 2 trials for dry-eye disease (RGN-259), pressure ulcers, and epidermolysis bullosa. No approval for therapeutic use.

1. [01]
   Goldstein AL, Hannappel E, Sosne G, Kleinman HK

   Thymosin β4: a multi-functional regenerative peptide

   Expert Opinion on Biological Therapy · 2012

   PubMed 22506816 ↗
2. [02]
   Sosne G, Ousler GW

   Thymosin beta 4 ophthalmic solution for dry eye — Phase 2

   Clinical Ophthalmology · 2015

   PubMed 26396493 ↗

• NCT02623244

  ARISE-3: RGN-259 in dry eye
  Phase 3Registry ↗

Preclinical only. No completed human clinical trials. The published evidence base is extensive rodent-model work, primarily from the Sikirić group in Zagreb.

1. [01]
   Sikirić P, et al.

   Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157

   Current Pharmaceutical Design · 2013

   PubMed 22950504 ↗
2. [02]
   Chang CH, et al.

   BPC 157 on tendon healing

   Journal of Applied Physiology · 2011

   PubMed 21680891 ↗DOI ↗
3. [03]
   Seiwerth S, et al.

   Stable gastric pentadecapeptide BPC 157 and wound healing

   Frontiers in Pharmacology · 2021

   PubMed 34220518 ↗

Preclinical only for BPC-157 generally. Oral bioavailability of the peptide is an active area of research; no approved indication.

1. [01]
   Sikirić P, et al.

   BPC 157 — gastric juice stability

   Current Pharmaceutical Design · 2013

   PubMed 22950504 ↗

As per individual-peptide entries: preclinical-only for both components.

No citations on file for this peptide. See product page for full specification.

GHK-Cu is approved as a cosmetic ingredient (INCI: Copper Tripeptide-1) in the EU, US, and other jurisdictions. No therapeutic approval.

1. [01]
   Pickart L, Margolina A

   Regenerative and Protective Actions of GHK-Cu — Gene Data Review

   International Journal of Molecular Sciences · 2018

   PubMed 30029425 ↗
2. [02]
   Pickart L, Vasquez-Soltero JM, Margolina A

   GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

   BioMed Research International · 2015

   PubMed 26236730 ↗

Cosmetic-approved ingredient (EU, US). No therapeutic approval.

1. [01]
   Pickart L, Margolina A

   GHK-Cu gene-expression review

   IJMS · 2018

   PubMed 30029425 ↗

Proprietary cosmetic-formulation blend. No approval for therapeutic use.

1. [01]
   Pickart L, Margolina A

   GHK-Cu gene-expression review

   IJMS · 2018

   PubMed 30029425 ↗

Cosmetic-formulation research blend. No therapeutic approval.

No citations on file for this peptide. See product page for full specification.

Investigational. Early Phase 1 trials for photoprotection in the 1990s; no regulatory approval for any indication.

1. [01]
   Dorr RT, Lines R, Levine N, et al.

   Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide

   Life Sciences · 1996

   PubMed 8878156 ↗

Afamelanotide (MT-1) is approved by the EMA and FDA for erythropoietic protoporphyria (EPP) under the trade name Scenesse®. Omega Grade supplies research-grade peptide only.

1. [01]
   Langendonk JG, Balwani M, Anderson KE, et al.

   Afamelanotide for Erythropoietic Protoporphyria

   New England Journal of Medicine · 2015

   PubMed 26132941 ↗DOI ↗

Bremelanotide is approved by the FDA (2019) for hypoactive sexual desire disorder in premenopausal women under the trade name Vyleesi®. Supplied by Omega Grade as research-grade peptide.

1. [01]
   Kingsberg SA, Clayton AH, Portman D, et al.

   Bremelanotide for Hypoactive Sexual Desire Disorder (RECONNECT)

   Obstetrics & Gynecology · 2019

   PubMed 31464739 ↗
2. [02]
   Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB

   Double-blind, placebo-controlled evaluation of PT-141 nasal spray in men with ED

   International Journal of Impotence Research · 2004

   PubMed 14973520 ↗

Cosmetic ingredient. No therapeutic approval.

No citations on file for this peptide. See product page for full specification.

Investigational. Phase 2 trials for post-operative ileus completed; no approval. Discontinued in its original clinical programme.

1. [01]
   Raun K, Hansen BS, Johansen NL, et al.

   Ipamorelin, the first selective growth hormone secretagogue

   European Journal of Endocrinology · 1998

   PubMed 9849822 ↗

Investigational. Phase 1 / 2 trials by ConjuChem (discontinued). Not approved.

1. [01]
   Teichman SL, Neale A, Lawrence B, et al.

   Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295

   Journal of Clinical Endocrinology & Metabolism · 2006

   PubMed 16332938 ↗

Investigational. Related to sermorelin. Not approved.

1. [01]
   Teichman SL, et al.

   Prolonged stimulation of GH by CJC-1295

   JCEM · 2006

   PubMed 16332938 ↗

Approved by the FDA (2010) for HIV-associated lipodystrophy under the brand name Egrifta® (Theratechnologies). Supplied by Omega Grade as research-grade peptide.

1. [01]
   Falutz J, Allas S, Blot K, et al.

   Metabolic effects of a growth hormone-releasing factor in patients with HIV

   New England Journal of Medicine · 2007

   PubMed 17659030 ↗
2. [02]
   Stanley TL, Feldpausch MN, Oh J, et al.

   Effect of Tesamorelin on Visceral Fat and Liver Fat

   JCEM · 2014

   PubMed 24471565 ↗

Sermorelin was approved as Geref® for paediatric GH-deficiency evaluation; the commercial product was discontinued in 2008. No current approved indication. Research use only.

1. [01]
   Walker RF

   Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

   Clinical Interventions in Aging · 2006

   PubMed 18046878 ↗

Preclinical / early clinical research peptide. No approved indication.

1. [01]
   Bowers CY, Momany FA, Reynolds GA, Hong A

   On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone

   Endocrinology · 1984

   PubMed 6546862 ↗

Research reagent. Extensively used in cell-culture and in vivo research. No clinical approval.

1. [01]
   Francis GL, Upton FM, Ballard FJ, et al.

   Insulin-like growth factors 1 and 2 in bovine colostrum — Long R3 IGF-1 characterization

   Biochemical Journal · 1988

   PubMed 2462404 ↗

Research peptide. No clinical trials. First described in 2015.

1. [01]
   Lee C, Zeng J, Drew BG, et al.

   The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis

   Cell Metabolism · 2015

   PubMed 25738459 ↗
2. [02]
   Reynolds JC, Lai RW, Woodhead JST, et al.

   MOTS-c as an exercise-induced regulator of age-dependent physical decline

   Nature Communications · 2021

   PubMed 33649336 ↗

NAD⁺ is a naturally occurring dinucleotide coenzyme, not a peptide. Precursor molecules (NR, NMN) are supplement-regulated in most jurisdictions. Research-grade NAD⁺ is supplied by Omega Grade for laboratory work only.

1. [01]
   Martens CR, Denman BA, Mazzo MR, et al.

   Chronic nicotinamide riboside supplementation in healthy middle-aged and older adults

   Nature Communications · 2018

   PubMed 29599478 ↗
2. [02]
   Trammell SAJ, Schmidt MS, Weidemann BJ, et al.

   Nicotinamide riboside is uniquely and orally bioavailable

   Nature Communications · 2016

   PubMed 27766967 ↗

Research reagent. Not therapeutic.

No citations on file for this peptide. See product page for full specification.

Preclinical research tool. No clinical trials. Small molecule, not a peptide.

1. [01]
   Neelakantan H, Vance V, Wetzel MD, et al.

   Selective and membrane-permeable small molecule inhibitors of NNMT — 5-amino-1-methylquinolinium

   Biochemical Pharmacology · 2018

   PubMed 29366977 ↗

Phase 2b obesity trial completed (did not meet primary endpoint). Marketed as a food ingredient in some jurisdictions. No therapeutic approval.

1. [01]
   Heffernan M, Summers RJ, Thorburn A, et al.

   The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

   Endocrinology · 2001

   PubMed 11397844 ↗

Preclinical research tool from the Burris laboratory. No clinical trials.

1. [01]
   Billon C, Sitaula S, Banerjee S, et al.

   Synthetic ERR agonists induce the phenotype of endurance exercise

   Science Advances · 2023

Registered for clinical use in Russia for cognitive and neuroprotective indications. No Western regulatory approval.

1. [01]
   Dolotov OV, Karpenko EA, Inozemtseva LS, et al.

   Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus

   Brain Research · 2006

   PubMed 16516871 ↗

Intranasal formulation — matches the Russian-registered clinical delivery route. Research use only outside Russia.

1. [01]
   Dolotov OV, et al.

   Semax modulates BDNF/trkB

   Brain Research · 2006

   PubMed 16516871 ↗

Registered for clinical use in Russia as an anxiolytic. No Western regulatory approval.

1. [01]
   Medvedev VE, Tereshchenko OP, Israelyan AY, et al.

   Optimization of treatment of anxiety with non-benzodiazepine anxiolytics selank and afobazole

   Neuroscience and Behavioral Physiology · 2015

   PubMed 25624024 ↗

Nasal spray matches the Russian clinical delivery route. Research use only outside Russia.

No citations on file for this peptide. See product page for full specification.

Preclinical research peptide. No approved clinical indication. Limited human research in sleep-physiology contexts (primarily 1980s European literature).

1. [01]
   Graf MV, Kastin AJ

   Delta-sleep-inducing peptide (DSIP): an update

   Peptides · 1986

   PubMed 3541890 ↗

Approved for methemoglobinemia treatment (IV, pharmaceutical grade only). Research-grade methylene blue is used extensively in cell biology, mitochondrial research, and neuroprotection studies.

1. [01]
   Rojas JC, Bruchey AK, Gonzalez-Lima F

   Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue

   Progress in Neurobiology · 2012

   PubMed 22705477 ↗

Proprietary research blend from ChemAesthetic. No published clinical evaluation of this specific formulation.

No citations on file for this peptide. See product page for full specification.

Consumables — not a peptide or pharmaceutical.

No citations on file for this peptide. See product page for full specification.

Consumable — diluent for lyophilised peptides.

No citations on file for this peptide. See product page for full specification.

Consumable — diluent.

No citations on file for this peptide. See product page for full specification.